Yes, semaglutide is a GLP-1 receptor agonist, meaning it mimics the hormone GLP-1 (glucagon-like peptide-1) that your body naturally produces. It’s one of the most widely prescribed drugs in this class, sold under the brand names Ozempic, Wegovy, and Rybelsus. What makes semaglutide different from the GLP-1 your body makes on its own is how long it lasts: natural GLP-1 breaks down in about two minutes, while semaglutide stays active for roughly a week.
How Natural GLP-1 Works
Your gut releases GLP-1 after you eat. This hormone signals your pancreas to produce insulin, slows down how quickly food leaves your stomach, and communicates with your brain to reduce appetite. It’s part of a finely tuned system that helps regulate blood sugar and energy balance.
The problem is that natural GLP-1 is destroyed almost immediately by an enzyme called DPP-4, giving it a half-life of roughly two minutes. That’s far too short for any therapeutic use. GLP-1 receptor agonists like semaglutide are engineered to resist that enzyme, letting the drug circulate in your body long enough to produce sustained effects. Semaglutide specifically is designed for once-weekly dosing, whether by injection or daily oral tablet.
What Semaglutide Is Approved For
Semaglutide comes in three brand-name versions, each with different approved uses:
- Ozempic is the injectable form approved for type 2 diabetes and lowering the risk of heart attack or stroke in people with type 2 diabetes and cardiovascular disease.
- Wegovy is the higher-dose injectable form approved for weight management in adults and adolescents 12 and older with obesity or overweight plus a weight-related health condition.
- Rybelsus is the oral tablet form, approved for improving blood sugar control in adults with type 2 diabetes.
All three contain the same active molecule. The differences come down to dosing and what the FDA has specifically approved each product to treat. Semaglutide is not approved for type 1 diabetes.
Injectable vs. Oral Semaglutide
One of the things that sets semaglutide apart from many other GLP-1 drugs is that it comes in a pill form (Rybelsus), not just an injection. But the two versions behave quite differently inside your body. The oral tablet has a bioavailability of only about 1% to 2% compared to the injection, meaning the vast majority of the pill’s active ingredient never reaches your bloodstream. To compensate, the oral dose is higher in milligrams, and it must be taken on an empty stomach with a small amount of water.
The injectable versions reach peak blood levels in about 48 to 96 hours and have a much longer effective half-life, which is why they work as a once-weekly shot. The oral form peaks in under two hours and clears faster, so it’s taken daily instead.
Weight Loss Effects
Semaglutide’s weight loss results drew enormous public attention. In the landmark STEP 1 trial, people taking the higher-dose injection lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. For someone weighing 220 pounds, that translates to roughly 33 pounds lost over about 16 months.
These effects come from semaglutide’s ability to reduce appetite at the brain level and slow gastric emptying, both of which naturally decrease how much food you eat. The weight loss tends to be gradual, partly because the dose is increased slowly over the first several months of treatment.
Cardiovascular Benefits
Beyond blood sugar and weight, semaglutide has shown meaningful heart benefits. The SELECT trial found that semaglutide reduced major cardiovascular events (heart attack, stroke, or death from cardiovascular causes) by 20% compared to placebo. Notably, this benefit appeared even in people who didn’t have diabetes but did have obesity and established cardiovascular disease. This is part of why the drug class has gained such broad clinical interest.
How Dosing Works
Regardless of the indication, semaglutide is started at a low dose and gradually increased. The standard starting dose for the injectable form is 0.25 mg once a week for the first four weeks. From there, the dose is raised in steps, typically every four weeks, to give your body time to adjust. For weight management, the target dose can go up to 2.4 mg weekly with Wegovy, or as high as 7.2 mg weekly with newer formulations.
This slow titration isn’t optional. Starting at a higher dose significantly increases the risk of gastrointestinal side effects, which are already the most common complaint with the drug.
Common Side Effects
The most frequent side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhea, and constipation. Nausea is especially common in the early weeks and during dose increases, and it tends to improve over time for most people. These effects are a direct consequence of how GLP-1 receptor agonists work. Slowing gastric emptying helps with appetite and blood sugar, but it also means food sits in your stomach longer, which can cause discomfort.
Less common but more serious concerns include inflammation of the pancreas and, in animal studies, thyroid tumors. Semaglutide has not been studied in people with a history of pancreatitis, and it carries a boxed warning about thyroid cancer risk based on the animal data.
How Semaglutide Compares to Other GLP-1 Drugs
Semaglutide belongs to a broader family of GLP-1 receptor agonists that includes liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). They all work through the same basic mechanism, but semaglutide has generally shown larger effects on both weight loss and blood sugar reduction in head-to-head comparisons. Its once-weekly dosing also makes it more convenient than older drugs in the class that require daily or twice-daily injections.
Newer combination drugs like tirzepatide (Mounjaro, Zepbound) target both the GLP-1 receptor and a second hormone receptor called GIP, producing even greater weight loss in clinical trials. But semaglutide remains the most widely studied single-target GLP-1 drug, with the broadest range of approved uses and the longest real-world track record in this newer wave of obesity treatments.